In the current landscape of cancer research, much attention is focused on the tumor microenvironment (TME) at both the primary site and established metastases. However, the early micrometastatic niche remains poorly understood. Researchers from the Hospital del Mar Research Institute (HMRI) have pinpointed T cell immunoglobulin and mucin domain 3 (TIM3) as a key vulnerability in tumor micrometastasis, revealing a new target to halt metastatic progression at its origin. Read More
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic inflammation and structural damage to the alveoli, with irreversible declined lung function. M1 pro-inflammatory macrophages mainly participate in airway inflammation and in tissue destruction, and are involved in COPD, but the mechanisms need to be elucidated. Read More
Graves disease (GD)-associated hyperthyroidism is an autoimmune disorder characterized by the presence of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), leading to excessive production of thyroid hormones. Read More
Acute respiratory distress syndrome (ARDS) is a life-threatening pulmonary condition marked by intense inflammation, alveolar damage and fluid accumulation in the lungs, often leading to respiratory failure. In a study recently published in Translational Research, researchers aimed to develop a more physiologically relevant model by combining two major ARDS contributors: gastric acid aspiration and ventilator-induced lung injury. Read More
Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder worldwide, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a decline in both motor and cognitive functions. Incretin-based therapies, initially designed for the treatment of type 2 diabetes, have demonstrated relevant neuroprotective effects in preclinical models of PD. Read More
Azole antifungal agents are widely used to treat invasive fungal infections (IFIs), which are life-threatening in immunocompromised patients such as those undergoing chemotherapy, transplantation or intensive care. Read More
Myopia, a leading cause of visual impairment globally, can progress to serious complications like retinal and choroidal degeneration. While atropine is commonly used to manage childhood myopia, its nonselective action on all five acetylcholine muscarinic receptor subtypes (M1-M5 receptors) can cause side effects such as pupil dilation and photophobia. Read More
Colorectal cancer (CRC) accounts for 9.3% of cancer-related deaths worldwide. The levels of circulating immune cells in patients with CRC have been reported to undergo significant alterations, concretely in lymphocyte subsets. Read More
Hanmi Pharmaceutical Co Ltd. has synthesized new heterobicyclic compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors and reported to be useful for the treatment of cancer. Read More
Work at Genecode AS has led to the identification of sulfonamide or sulfone compounds acting as GFRα1-RET receptor complex activators potentially useful for the treatment of neurological disorders. Read More
Idorsia Pharmaceuticals Ltd. has patented macrocyclic compounds acting as orexin OX2 receptor agonists reported to be useful for the treatment of obesity, pain, fatigue, inflammation, cognitive, sleep, eating and mood disorders. Read More
Forx Therapeutics AG has discovered new bicyclo heteroaryl poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. Read More
